Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Nov 12, 2021
Atea Announces Update of Clinical Studies Evaluating AT-527 for COVID-19 in the Outpatient Setting
| Name of listed company: | Chugai Pharmaceutical Co., Ltd. |
| Code number: | 4519 (1st Section of Tokyo Stock Exchange) |
| Head office: | 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo |
| President & CEO: | Osamu Okuda |
| Inquiries to: | Toshiya Sasai |
| Head of Corporate Communications Dept. | |
| Tel:+81-(0)3-3273-0554 |
Chugai Pharmaceutical Co., Ltd. announced that Atea issued a press release on November 11 regarding update of MOONSONG study and MORNINGSKY study evaluating the RNA polymerase inhibitor AT-527 for COVID-19 in the outpatient setting.
Please refer to the link below for details of the press release:
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results
https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-provides-clinical-and-corporate-update-0
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Tomoko Shimizu
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
